1. |
McDonald et. al.88 McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am 1986;68(02):235–242
|
1986 |
84 meses |
146 |
Ressecção ampla
curetagem + broca
|
7%
34%
|
2. |
Campanacci et al.99 Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987;69(01):106–114
|
1987 |
2–44 anos |
280 |
Ressecção ampla |
0% |
Excisão marginal |
8% |
Excisão intralesional |
27% |
3. |
O’Donnel et al.1010 O’Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ. Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994;76 (12):1827–1833
|
1994 |
4 anos |
60 |
Curetagem + PMMA |
42% |
Curetagem + PMMA + broca |
17% |
4. |
Blackley et al.1111 Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 1999;81(06):811–820
|
1999 |
80 meses |
59 |
Curetagem + broca |
12% |
5. |
Trieb et al.66 Trieb K, Bitzan P, Lang S, Dominkus M, Kotz R. Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol 2001;27(02): 200–202
|
2001 |
11 anos |
47 |
Curetagem + broca |
21% |
Curetagem + broca + fenol |
25% |
6. |
Turcotte et. al.1212 Turcotte RE, Wunder JS, Isler MH, et al; Canadian Sarcoma Group. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 2002;(397):248–258
|
2002 |
60 meses |
156 |
Ressecção ampla |
16% |
Curetagem +/- broca +/- fenol |
18% |
7. |
Saiz et al.1313 Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S. Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res 2004;(424):221–226
|
2004 |
76 meses |
40 |
Curetagem + broca + fenol + PMMA |
13% |
8. |
Su et al.1414 Su YP, Chen WM, Chen TH. Giant-cell tumors of bone: an analysis of 87 cases. Int Orthop 2004;28(04):239–243
|
2004 |
62 meses |
87 |
Ressecção ampla |
3% |
Curetagem + fenol + broca |
18% |
9. |
Prosser et al.1515 Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res 2005;(435): 211–218
|
2005 |
70 meses |
137 |
Curetagem + broca |
19% |
10. |
Malek et al.1616 MalekF, Krueger P, Hatmi ZN, Malayeri AA,FaezipourH, O’Donnell RJ. Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop 2006;30(06):495–498
|
2006 |
48 meses |
40 |
Curetagem + broca |
33% |
11. |
Lewis et al.1717 Lewis VO, Wei A, Mendoza T, Primus F, Peabody T, Simon MA. Argon beam coagulation as an adjuvant for local control of giant cell tumor. Clin Orthop Relat Res 2007;454(454):192–197
|
2007 |
73 meses |
37 |
Curetagem + plasma de argônio + PMMA |
8,3% |
13. |
Balke et al.1818 Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008;134(09):969–978
|
2008 |
60 meses |
214 |
Ressecção ampla |
0% |
Curetagem |
65% |
Curetagem + broca |
22% |
Curetagem + PMMA + broca |
18% |
Curetagem + PMMA + broca + H2O2
|
12% |
14. |
Kivioja et al.1919 Kivioja AH, Blomqvist C, Hietaniemi K, et al. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008;79(01):86–93
|
2008 |
5 anos |
294 |
Excisão ampla/ marginal |
12% |
Curetagem |
51% |
Curetagem + PMMA |
23% |
15. |
Errani et al.2020 Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 2010;36(01):1–7
|
2010 |
91 meses |
349 |
Ressecção ampla |
12% |
Curetagem + broca + fenol |
51% |
Curetagem + broca + fenol + PMMA |
22% |
16. |
Klenke et al.2121 Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011;469(02):591–599
|
2011 |
108 meses |
118 |
Ressecção ampla |
5% |
Curetagem + broca |
32% |
Curetagem + fenol + broca |
34% |
Curetagem + PMMA + broca + fenol |
15% |
17. |
Benevenia et al.2222 Benevenia J, Patterson FR, Beebe KS, Abdelshahed MM, Uglialoro AD. Comparison of phenol and argon beam coagulation as adjuvant therapies in the treatment of stage 2 and 3benign-aggressive bone tumors. Orthopedics 2012;35(03):e371–e378
|
2012 |
10 meses |
93 |
Curetagem + fenol |
17,1% |
Curetagem + plasma de argônio |
14,8% |